e-learning
resources
Vienna 2009
Sunday, 13.09.2009
Drug treatment of childhood asthma: the controversies and the issues
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Safety of omalizumab therapy in children with allergic asthma
H. Milgrom, A. Fowler-Taylor, C. Fernandez-Vidaurre, S. Jayawardene (Denver, East Hanover, United States Of America)
Source:
Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Session:
Drug treatment of childhood asthma: the controversies and the issues
Session type:
Thematic Poster Session
Number:
1214
Disease area:
Paediatric lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Milgrom, A. Fowler-Taylor, C. Fernandez-Vidaurre, S. Jayawardene (Denver, East Hanover, United States Of America). Safety of omalizumab therapy in children with allergic asthma. Eur Respir J 2009; 34: Suppl. 53, 1214
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Safety and efficacy of omalizumab in children with allergic asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011
Real-life long-term omalizumab therapy in children with severe allergic asthma
Source: Eur Respir J 2015; 46: 856-859
Year: 2015
Efficacy and safety of ciclesonide in the treatment of patients with persistent allergic or non-allergic asthma
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012
Assesment of long-term omalizumab treatment in severe allergic asthma
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Year: 2012
Systemic steroid use in children with allergic (IgE-mediated) asthma receiving omalizumab
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
Efficacy of montelukast in patients with concomitan persistent allergic rhinitis and asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 663s
Year: 2006
Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003
Efficacy of omalizumab in patients with concomitant allergic asthma and atopic dermatitis: a pilot study
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
Source: Eur Respir J 2002; 20: 73-78
Year: 2002
The role of omalizumab or rhuMAb-E25 in the treatment of allergic rhinitis
Source: Eur Respir J 2004; 24: 330
Year: 2004
Treatment of co-morbid allergic asthma and perennial allergic rhinitis with the anti-IgE agent omalizumab
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003
The effectiveness of omalizumab in steroid-dependent asthma patients
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010
Treatment and outcomes in patients with asthma and allergic rhinitis
Source: Eur Respir J 2005; 26: Suppl. 49, 576s
Year: 2005
Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Follow-up of patients with moderate-severe allergic asthma treated with omalizumab
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Clinical and histological impact of omalizumab in oral corticosteroid-dependent severe allergic asthma
Source: International Congress 2019 – Novel findings from asthma clinical trials
Year: 2019
The evaluations of allergic rhinitis symptoms in patients with asthma and allergic rhinitis with the addiing of montelukast in asthma treatment
Source: Eur Respir J 2004; 24: Suppl. 48, 124s
Year: 2004
Effect of omalizumab treatment on allergic comorbidities in patients with severe allergic asthma – real life experience from Czech Anti-IgE Registry
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017
Cost of asthma rescue/acute and allergy medications among asthmatic patients on controller therapy
Source: Eur Respir J 2004; 24: Suppl. 48, 344s
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept